Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Several of them were approved in the past year, and each one was the first treatment of any kind for the condition it targets. This page collects every approval and rejection Gene Tech Times has covered, so you can see the pattern rather than one headline at a time.

The approvals we covered
Fayuvi, the first treatment for Sanfilippo syndrome type A (September 2026). Ultragenyx's UX111 is an AAV9 gene therapy for a disease sometimes called childhood Alzheimer's. Before it, there was nothing — not a partial treatment, nothing.
Voceryq, the first plasmid DNA immunotherapy (November 2026). Approved for recurrent respiratory papillomatosis, a condition that forces patients through repeated surgeries to keep their airway open. It uses a circular piece of DNA rather than a virus to deliver its payload.
Otarmeni, the first gene therapy for genetic hearing loss (April 2026). A landmark because hearing loss had long been discussed as a gene therapy target without reaching approval.
Kresladi, the first gene therapy for severe LAD-I (March 2026). Leukocyte adhesion deficiency type I prevents white blood cells from reaching infections. Most children with the severe form did not survive early childhood without a transplant.
Casgevy expands to children as young as 2 (July 2026). Not a new approval but an important one: the first CRISPR medicine extended to toddlers with sickle cell disease and transfusion-dependent beta-thalassemia.

The rejections, which matter just as much
Approval is not the default outcome, and the refusals show where the FDA draws its lines.
FDA Rejects Ultragenyx's Gene Therapy for Sanfilippo Syndrome (July 2025). The same programme that was later approved as Fayuvi. The gap between those two stories is the clearest illustration we have covered of what a complete response letter actually means: not "no", but "not yet, and here is what is missing".
Capricor's Shares Drop After FDA Rejects Deramiocel (July 2025). A cell therapy for the heart problems in Duchenne muscular dystrophy.
What the pattern shows
Three things recur across these decisions:
First-in-disease approvals are accelerating. Four of the five above were the first treatment of any kind for their condition.
The FDA is increasingly willing to accept surrogate endpoints — an early biological signal rather than a proven clinical outcome — in exchange for confirmatory studies afterwards. Our coverage of the FDA's potency assurance guidance and its proposal to cover many mutations under one approval explains the machinery behind that shift.
Safety questions do not stop at approval. The investigation into cancer risk with Zolgensma, years after it was approved, is the clearest example.
Getting the full list
We keep a free one-page reference, Every FDA-Approved Gene Therapy at a Glance, covering all 33 with what each treats and when it was approved. It goes out to subscribers of the Gene Tech Times Briefing — you can get it from our homepage.
The bottom line
Gene therapy has moved from a field with a handful of approvals to one adding several a year, most of them first-ever treatments for diseases that had none. The rejections are part of the same story, and they show the standard is still real.
Keep exploring with Gene Tech Times
Free guide: subscribe to the Gene Tech Times Briefing on our homepage and get Every FDA-Approved Gene Therapy at a Glance in your inbox.
Learn it properly: Gene Therapy 101 walks you from DNA to approved therapies in 8 animated modules with quizzes.
Watch: 30-second gene therapy Shorts and in-depth lessons on Gene Tech Times Academy.
Read: The Life-Changing Power of Gene Therapy, real stories from the families behind the science.
As an Amazon Associate, Gene Tech Times earns from qualifying purchases.
— T.N., Gene Tech Times




Comments